Back to search results

Observational Study of Brain NAD in Alzheimer's Disease

This observational study aims to understand the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease (AD). Researchers want to see if brain NAD levels are lower in individuals with AD compared to those without the disease. You may be able to join if you are between 65 and 80 years old, can come to the study site, are verbal and can walk. If you have Alzheimer's, your diagnosis must be confirmed by your doctor using specific tests like an amyloid PET-scan or an FDA-approved CSF or blood test. The study will measure brain NAD levels using a special type of brain scan called magnetic resonance spectroscopy (MRS) at the start of the study and again eight months later.

Study design
This is an observational study with a planned enrollment of 20 participants, including people with and without Alzheimer's disease.
What's involved
You would have two brain imaging sessions using magnetic resonance spectroscopy (MRS), one at the start and another eight months later.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 8 months after enrollment, with a second measurement taken at that time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07127510

Brain NAD in Alzheimer's Disease

Recruiting
Not specifiedAges 65–80Observational
Florida Atlantic University
~20 participants
Updated 2026-03-24 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brain NAD
Measured over At enrollment and 8 months after enrollment

Conditions

Alzheimer Disease (AD)

Explore related trials

Alzheimer's DiseaseAmyloid

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Corinne Lasmezas, PhD · PRINCIPAL_INVESTIGATOR · Florida Atlantic University

Who to contact

FAU Clinical Research Unit Central Contact
[email protected]
561-235-4467
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
Age 65 to 80 included.
People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.

Exclusion

Under the age of 65 or over the age of 80.
Advanced dementia such that the person would require sedation for undergoing an MRI scan.
Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
Having a history of seizures.
Working at night.
Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
People with no AD: MoCA test result lower than 26.

What this trial measures

  • Brain NADAt enrollment and 8 months after enrollment

    NAD levels measured by 1H-MRS